(OFIX) Orthofix Medical - Overview
Stock: Bone Stimulators, Spine Implants, Biologics, Navigation Systems, Limb Fixation
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 38.0% |
| Relative Tail Risk | -8.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.87 |
| Alpha | -47.23 |
| Character TTM | |
|---|---|
| Beta | 0.897 |
| Beta Downside | 1.105 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.41% |
| CAGR/Max DD | -0.28 |
Description: OFIX Orthofix Medical December 27, 2025
Orthofix Medical Inc. (NASDAQ:OFIX) is a U.S.–based medical-technology firm that designs, manufactures, and distributes spine- and orthopedics-focused devices across North America, Europe, and Brazil. The company operates two business lines: Global Spine, which offers bone-growth stimulators, fixation and motion-preservation implants, biologics, and a 7D flash navigation platform for spine and cranial surgery; and Global Orthopedics, which supplies external and internal fixation systems for limb reconstruction and deformity correction, all integrated with digital workflow tools.
In FY 2023 the company generated roughly $210 million in revenue, with the Global Spine segment contributing about 70 % of sales, while the Global Orthopedics segment accounted for the remainder. Orthofix’s revenue growth has been modest (≈3 % YoY) and the firm continues to post a net loss, reflecting ongoing R&D spend and the need to scale its digital navigation solutions. The firm employs roughly 600 staff and sells primarily through a mix of direct sales reps and regional distributors to hospitals and health-system networks.
Key market drivers include an aging population that is expanding the global spine-device market at a projected CAGR of 6 % through 2030, and increasing adoption of image-guided and robot-assisted surgical technologies that Orthofix’s 7D navigation system targets. Reimbursement trends under Medicare and private insurers also shape product pricing and adoption rates, making payer policy a critical economic factor for the company.
For a deeper quantitative view, you may explore the OFIX profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -119.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 5.11 > 1.0 |
| NWC/Revenue: 28.64% < 20% (prev 28.60%; Δ 0.04% < -1%) |
| CFO/TA 0.04 > 3% & CFO 29.4m > Net Income -119.1m |
| Net Debt (138.5m) to EBITDA (5.26m): 26.32 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.8m) vs 12m ago 3.32% < -2% |
| Gross Margin: 68.27% > 18% (prev 0.68%; Δ 6759 % > 0.5%) |
| Asset Turnover: 96.21% > 50% (prev 90.36%; Δ 5.85% > 0%) |
| Interest Coverage Ratio: -3.22 > 6 (EBITDA TTM 5.26m / Interest Expense TTM 28.1m) |
Altman Z'' -1.27
| A: 0.28 (Total Current Assets 394.2m - Total Current Liabilities 159.8m) / Total Assets 832.6m |
| B: -0.44 (Retained Earnings -366.1m / Total Assets 832.6m) |
| C: -0.11 (EBIT TTM -90.3m / Avg Total Assets 850.2m) |
| D: -0.93 (Book Value of Equity -361.5m / Total Liabilities 390.1m) |
| Altman-Z'' Score: -1.27 = CCC |
Beneish M -3.25
| DSRI: 1.00 (Receivables 130.8m/124.8m, Revenue 818.1m/784.2m) |
| GMI: 1.00 (GM 68.27% / 68.05%) |
| AQI: 0.89 (AQ_t 0.34 / AQ_t-1 0.39) |
| SGI: 1.04 (Revenue 818.1m / 784.2m) |
| TATA: -0.18 (NI -119.1m - CFO 29.4m) / TA 832.6m) |
| Beneish M-Score: -3.25 (Cap -4..+1) = AA |
What is the price of OFIX shares?
Over the past week, the price has changed by -3.25%, over one month by -17.95%, over three months by -12.81% and over the past year by -30.70%.
Is OFIX a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OFIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21 | 64.4% |
| Analysts Target Price | 21 | 64.4% |
| ValueRay Target Price | 11.5 | -10.4% |
OFIX Fundamental Data Overview February 03, 2026
P/S = 0.6404
P/B = 1.184
P/EG = 3.1578
Revenue TTM = 818.1m USD
EBIT TTM = -90.3m USD
EBITDA TTM = 5.26m USD
Long Term Debt = 157.2m USD (from longTermDebt, last quarter)
Short Term Debt = 3.97m USD (from shortTermDebt, last quarter)
Debt = 204.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 138.5m USD (from netDebt column, last quarter)
Enterprise Value = 662.4m USD (523.9m + Debt 204.5m - CCE 65.9m)
Interest Coverage Ratio = -3.22 (Ebit TTM -90.3m / Interest Expense TTM 28.1m)
EV/FCF = -228.4x (Enterprise Value 662.4m / FCF TTM -2.90m)
FCF Yield = -0.44% (FCF TTM -2.90m / Enterprise Value 662.4m)
FCF Margin = -0.35% (FCF TTM -2.90m / Revenue TTM 818.1m)
Net Margin = -14.56% (Net Income TTM -119.1m / Revenue TTM 818.1m)
Gross Margin = 68.27% ((Revenue TTM 818.1m - Cost of Revenue TTM 259.5m) / Revenue TTM)
Gross Margin QoQ = 72.23% (prev 68.69%)
Tobins Q-Ratio = 0.80 (Enterprise Value 662.4m / Total Assets 832.6m)
Interest Expense / Debt = 2.29% (Interest Expense 4.68m / Debt 204.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -71.3m (EBIT -90.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.47 (Total Current Assets 394.2m / Total Current Liabilities 159.8m)
Debt / Equity = 0.46 (Debt 204.5m / totalStockholderEquity, last quarter 442.5m)
Debt / EBITDA = 26.32 (Net Debt 138.5m / EBITDA 5.26m)
Debt / FCF = -47.77 (negative FCF - burning cash) (Net Debt 138.5m / FCF TTM -2.90m)
Total Stockholder Equity = 465.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.01% (Net Income -119.1m / Total Assets 832.6m)
RoE = -25.59% (Net Income TTM -119.1m / Total Stockholder Equity 465.6m)
RoCE = -14.49% (EBIT -90.3m / Capital Employed (Equity 465.6m + L.T.Debt 157.2m))
RoIC = -11.45% (negative operating profit) (NOPAT -71.3m / Invested Capital 622.6m)
WACC = 7.14% (E(523.9m)/V(728.4m) * Re(9.22%) + D(204.5m)/V(728.4m) * Rd(2.29%) * (1-Tc(0.21)))
Discount Rate = 9.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.34%
Fair Price DCF = unknown (Cash Flow -2.90m)
EPS Correlation: -39.81 | EPS CAGR: -7.99% | SUE: 1.12 | # QB: 1
Revenue Correlation: 86.32 | Revenue CAGR: 14.18% | SUE: 2.22 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=+0.105 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.70 | Chg30d=+0.280 | Revisions Net=+1 | Growth EPS=+3.7% | Growth Revenue=+5.6%